BioNTech to invest in Autolus, gaining CAR-T manufacturing capacity

08 Feb 2024
firstwordpharma.com
License out/inImmunotherapyPhase 2Cell TherapyVaccine
BioNTech continues to spend its windfall from COVID-19 vaccinesCOVID-19 vaccines in a diversified manner, with the latest move focused on leveraging Autolus’ CAR-T manufacturing capacity. Chief executive Ugur Sahin said the deal, which will see BioNTech invest $200 million in Autolus, allows “us to expand our BNT211 programme into trials for multiple cancer indications in a cost-efficient way.”
BNT211 is an autologous Claudin-6-targeting CAR-T cell therapy candidate that is expected to enter a pivotal Phase II study in second-line germ cell tumours later this year.
The parties also entered a licensing agreement, with BioNTech making a $50 million cash payment for royalty rights on Autolus’ obecabtagene autoleucel (obe-cel). The cell therapy is currently under review by the FDA for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia, with a decision expected by November 16.
As part of the deal, BioNTech will support the potential launch of obe-cel, as well as expanding its development programme.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.